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Background:Metastatic prostate cancer is a clonally heterogeneous disease state characterized by progressive
somatic perturbations. The aim of this study was to identify cell free DNA- (cfDNA-) based alterations and
their associations with outcomes in progressive metastatic prostate cancer.
Methods: In this longitudinal prospective cohort study plasma cfDNA/circulating tumor DNA (ctDNA) was
analyzed before, during, and after androgen deprivation therapy (ADT) in 4 independent patient groups rang-
ing from untreated metastatic hormone sensitive prostate cancer (mHSPC) to metastatic castrate resistant
prostate cancer (mCRPC). Next generation sequencing was performed on ctDNA and germline DNA to charac-
terize alterations and associations with clinical outcomes were determined for each group.
Findings: cfDNA yields were different in progressive mHSPC and mCRPC states (P< .001). In mHSPC, a higher
than median ctDNA fraction was predictive of shorter time to ADT failure (HR, 2.29 [95% CI, 1.134.65]; Log-
Rank P = .02). cfDNA, ctDNA taken with volume of metastatic disease in mHSPC and with alkaline phosphatase
levels prognosticated survival better than clinical factors alone in mHSPC and mCRPC states (Log Rank P = 0.03).
ctDNA-based AR, APC mutations were increased in mCRPC compared to mHSPC (P< ¢05).TP53 mutations, RB1
loss, and AR gene amplifications correlated with poorer survival in mCRPC. Mutations in multiple DNA repair
genes (ATM, BRCA1, BRCA2, CHEK2) were associated with time to ADT treatment failure and survival in mHSPC.
Interpretation: ctDNA fraction can further refine clinical prognostic factors in metastatic prostate cancer.
Somatic ctDNA alterations have potential prognostic, predictive, and therapeutic implications in metastatic
prostate cancer management.
Funding: Several funding sources have supported this study. A full list is provided in the Acknowledgments.
No funding was received from Predicine, Inc. during the conduct of the study.
© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
Circulating tumor DNA
Metastatic prostate cancer
Genomic alterations).
B.V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)1. Introduction
Prostate cancer is a significant public health concern. According to
the GLOBOCAN 2018 database, there are 1¢26 million cases of pros-
tate cancer reported each year globally and over 375000 associated
Research in context
Evidence before this study
We consulted literature published after 2012, as before this time,
genomic sequencing of tissue metastases or liquid biopsies were
not reported for prostate cancer. Somatic mutational variations
have been extensively reported in metastatic castrate resistant
prostate cancer (mCRPC) since 2015 in tissue and in liquid biop-
sies. However, studies have yet to elucidate comprehensively
the evolution in the continuum of the genomic landscape from
metastatic hormone sensitive prostate cancer (mHSPC) to clini-
cal and radiographically progressive mCRPC states, and studies
have not explored its impact on clinical outcomes.
Added value of this study
This study provides an atlas of the somatic changes observed in
each of the progressive metastatic prostate cancer states, start-
ing with untreated mHSPC to treated mHSPC and mCRPC states.
We were able to uncover the underlying clonal evolution in the
continuum of these progressive metastatic states, which has
not been previously published. Because clinical follow-up was
obtained, we were also able to comprehensively profile the
clinical relevance of the structural DNA-based variations. Until
now, the selection of patients for treatments additional to
androgen deprivation therapy has been guided using clinical
prognostic factors (Gleason Score, the presence of visceral
metastases, and/or the number of skeletal metastases).
Implications of all the available evidence
Our results provide insights based on the circulatory and mea-
surable tumor genome and the presence or absence of key
genomic perturbations. We observed that circulating tumor
DNA yields is a key prognostic factor in each state of metastatic
progression; this further refines currently recognized clinical
prognostic factors. This finding may potentially assist in select-
ing patients for the intensification of upfront systemic treat-
ment. Similarly, we identified specific genes in which
alterations were associated with clinical outcomes, which may
also have a potential for therapeutic impact.
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hormone-sensitive (mHSPC) and metastatic castrate-resistant
(mCRPC) prostate cancer states include androgen receptor pathway
inhibitors, cytotoxic chemotherapy, radioisotope treatment with
radium-223, ex vivo purged autologous cellular immunotherapy
with sipuleucel-T [3], and the poly (ADP-ribose) polymerase gamma
inhibitor olaparib, which has received FDA breakthrough designation
[4]. Several of these drug options have demonstrated clinical benefit
when combined with androgen deprivation therapy (ADT) to treat
patients with mHSPC [59], non-mCRPC, and high-risk locally
advanced nonmetastatic disease [8,10]. However, drug choices are
currently not selected on the basis of individual genomic variant pro-
filing in any state of progressive disease.
The genomic landscape of solid metastatic tumors in the castrate-
resistant state harbor a high degree of stage-specific somatic altera-
tions and tumor heterogeneity compared to localized prostate cancer
[1113]. Stage-specific somatic alterations in individual patient
tumors may aid in developing predictive, therapeutic, and prognostic
molecular biomarkers, allowing for targeted drugpairing choices
with greater precision and therapeutic gain. As the genomic land-
scapes of mHSPC leading to mCRPC have not been well described,
challenges remain for drug-targeted mutational profiling in patientswith advanced prostate cancer. Our group previously reported the
mutational landscape of solid metastases in patients with treatment-
naive mCRPC before abiraterone acetate/prednisone drug therapy
[11]. We successfully sequenced tumor nucleic acids from solid
metastases, including bone, but obtaining a high yield and purity of
nucleic acids from skeletal metastases before and after treatments
was particularly challenging [14]. Additionally, the invasiveness of
performing metastatic solid tissue biopsies for sequencing is not fea-
sible in routine clinical practice. It is also impractical to perform met-
astatic solid tissue serial biopsies that capture an evolving genomic
landscape to monitor minimal residual disease or identify pharmaco-
dynamic markers before and after drug initiation under treatment
selection pressure.
We report the results of a prospective longitudinal cohort study,
in which the individual genomic variants of patients with 4 different
metastatic prostate cancer states, starting with treatment-naive
mHSPC and leading to mCRPC, were profiled using plasma circulating
tumor DNA (ctDNA) sequencing. We aimed to characterize tumor-
associated copy number alterations (CNAs), single-nucleotide varia-
tions (SNVs), and commonly observed rearrangements in indepen-
dent cohorts of patients with metastatic prostate cancer before,
during, and at the time of ADT failure, defined both on the basis of
biochemical relapse and clinical/radiographic progression criteria.
We also used a second independent castrate-resistant prostate cancer
cohort to validate ctDNA-based genomic variants. In doing so, we
have comprehensively profiled the genomic landscape across the
spectrum of metastatic prostate cancer and have deciphered key clin-
ical and molecular insights into this heterogeneous disease.
2. Materials and methods
2.1. Patient enrollment and sample collection
Patients with metastatic prostate cancer were prospectively
enrolled between September 2009 and March 2014 in a single ter-
tiary-level cancer center (Mayo Clinic, Rochester, MN) after obtaining
written informed consent for serial blood collections, as previously
described [1518]. A second cohort of clinical mCRPC patients was
enrolled from Monash University (Australia). Methods for circulating
free DNA (cfDNA) and germline DNA (gDNA) extraction are detailed
in Supplementary Methods.
2.2. Library preparation, capture, and sequencing
Five to thirty nanograms of extracted cfDNA and 40 ng per unique
patient sample of fragmented gDNA were subjected to library con-
struction, including end-repair dA-tailing and adapter ligation.
Ligated library fragments with appropriate adapters were amplified
via PCR. The amplified DNA libraries were then checked using Bioa-
nalyzer 2100, and samples with yields > 700 ng were proceeded to
hybrid capture. Details of library capture, hybridization, and the 120-
gene PredicineLDT panel are provided in Supplementary Methods.
2.3. Analyses of next generation sequencing data from cfDNA
Data were analyzed using the Predicine in-housedeveloped
analysis pipeline, which starts from the raw sequencing database call
files (¢BCL) and outputs the final mutation calls. Briefly, the pipeline
first does an adapter trim, barcode checking, and correction. Cleaned
paired FASTQ files were aligned to human reference genome build
hg19 using Burrows-Wheeler Aligner [19]. Consensus bam files are
then derived by merging paired-end reads originated from the same
molecules (based on mapping location and unique molecular identi-
fiers) as single strand fragments. Single strand fragments from the
same double strand DNA molecules were further merged as double
stranded. By using error suppression method described in [20], both
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cess. Candidate variants consisting of point mutations and small
insertions and deletions were identified by comparing with local var-
iant background [20] (defined based on plasma samples from health
donors and historical data). Variants were further filtered by log-
odds (LOD) threshold [21], base quality and mapping quality thresh-
olds, repeat regions and other quality metrics. Detailed variant filter-
ing and analysis of sequencing data from gDNA are provided under
“Supplementary Methods”.
2.4. CNV estimation methods
We first calculated the on-target unique fragment coverage on the
basis of consensus sequence from BAM files; the fragment was also
corrected for GC bias. The GC-adjusted unique fragment was then
compared against corresponding coverage from a group of normal
reference samples to estimate the significance of the copy number
variant. Amplification or deletion of a gene copy number with an
absolute z-score > 2¢58 (the inverse of the cumulative distribution
function of a Gaussian distribution at 99¢5% confidence level) were
deemed as true events. Methods used in detection of DNA rearrange-
ments are elaborated in Supplementary Methods.
2.5. ctDNA fraction calculation
ctDNA fraction was estimated on the basis of the allele fractions of
autosomal somatic mutations, as described previously [22]. Briefly,
the mutant allele fraction (MAF) and the ctDNA fraction were related,
as MAF=(ctDNA*1)/([1-ctDNA]*2+ctDNA*1); therefore, ctDNA=2/([1/
MAF]+1). Somatic mutations in genes with a detectable copy number
amplification were omitted from ctDNA fraction estimates. ctDNA
fractions were then estimated as the product of ctDNA fraction and
total cfDNA yield in the corresponding sample following a normaliza-
tion by plasma volume.
2.6. Plasma tumor mutational burden calculation
Plasma tumor mutational burden (pTMB) was defined as the
number of somatic coding SNVs, including synonymous and nonsy-
nonymous variants, detected in the plasma samples after removing
germline single-nucleotide polymorphisms. The full 240 KB coding
regions covered by the PredicineLDT panel (Predicine Inc., Hayward,
CA, USA) were used to calculate pTMB. Only samples with the maxi-
mum somatic allelic frequency (MSAF) 0.5% were analyzed for
pTMB. The 0.5% of MSAF was selected according to the assay perfor-
mance metrics (shown in the Supplementary Figure S1) and previous
publication [1].
2.7. Statistical analysis methods
Wilcoxon signed rank test was used to evaluate statistical differ-
ences of cfDNA yield/ctDNA fraction between patients with different
states of progressive mHSPC and mCRPC due to skewed distribution
of DNA yields. Paired Wilcoxon tests were performed to examine dif-
ferences of cfDNA/ctDNA and pTMB between matched untreated
mHSPC patients and 3-month post-ADT mHSPC patients and
between untreated mHSPC and mCRPC patients. Fisher Exact tests
were used to calculate Odds Ratios and estimate the significance of
differences of the genomic alterations among different disease states.
Kruskal Wallis tests were performed to compare the statistical differ-
ences of ctDNA, cfDNA, TMB among patients in the different states.
Survival analyses was used to evaluate associations of feature varia-
bles with ADT failure and overall survival (OS). ADT failure was defined
as the time from a patient initiating continuous ADT therapy until bio-
chemical relapse with 2 successive serum PSA readings above the
nadir, with the second reading taken at least 4 weeks apart. A patientwas right censored if the patient did not have PSA relapse at the time
of the last follow-up or at the cutoff date of the analysis. Similarly,
overall survival was calculated as the difference between the date of
study enrollment to the date of death or to the last follow-up for alive
patients (right censored) at the time of the cutoff date of the analysis.
For a given feature variable, Cox proportional hazards regression and
the Log-rank test were used in univariate and multivariate analyses to
assess the significance of its association with ADT failure or OS. Glea-
son score, ctDNA fraction, and metastatic volume (for time to ADT fail-
ure)/alkaline phosphatase levels (for OS) were included in the
multivariate analysis as co-variables. To dichotomize the patient
cohorts, the median cutoff was used for ctDNA fraction and alkaline
phosphatase levels. A high Gleason score patient was defined as a
patient with Gleason scores greater than 7, and a low Gleason score
was defined as scores less than or equal to 7. The definition of meta-
static volume was based on the CHAARTED trial [6]. Scaled Schoenfeld
residuals and deviance residuals with time were examined to ensure
the validity of the Cox regression assumptions. All tests of statistical
significance were two-tailed, with a significance set at P ¢05. To
account for multiple hypothesis testing, adjusted P values by the Ben-
jamini and Hochberg procedure were also reported [23].
All statistical analyses were performed using R version 3¢5¢3 [24],
and all tests of statistical significance were two-tailed with a signifi-
cance set at P ¢05.
2.8. Role of the funding source
This study was based on a non-commercial collaboration between
academic institutions. No funding was received from Predicine, Inc.
during the conduct of the study. The discussion to submit the paper
for publication was made by MK, AA, JU, and SJ; the final decision
was made by MK.
3. Results
Between September 2009 and January 2013, 303 metastatic pros-
tate cancer patients were prospectively enrolled at the Mayo Clinic
and followed until death. A second biobank of metastatic prostate can-
cer patients at Monash University recruited prospective patients
between 2016 and 2018. Metastatic prostate cancer patients in both
biobanks with adequate plasma volume from whole blood for cfDNA
extraction were included, and for the larger Mayo Clinic cohort, which
had adequate longitudinal follow-up, the cutoff date for all analyses
was September 1, 2018. The workflow for the final 250 (82%) patients
with analyzable cfDNA sequencing data with clinical outcomes is
shown in Supplementary Figure S1. Individual deidentified patient-
level results can be found in the Supplementary Raw Data.
The study cohort was divided into 4 independent groups. The first
group, “Untreated mHSPC,” included mHSPC patients whose first
sample collection was performed before ADT initiation. Several, but
not all, patients in this group had a second serial blood sample collec-
tion after 3 months of ADT; these serially collected patients were
labeled the “3-month mHSPC” subgroup. The second group, “mHSPC
on ADT,” included patients who were enrolled at the time of the first
sample collection while undergoing continuous ADT. These patients
had a biochemical response confirmed by stable to lower serum pros-
tate-specific antigen (PSA) levels compared to pre-ADT initiation lev-
els. The third independent group, “Biochemical progressive mCRPC,”
included patients with biochemical progression on ADT (defined as
serially rising PSA levels above a previous PSA nadir) and castrate tes-
tosterone levels at the time of first blood sample collection and before
a secondary hormonal maneuver or any additional new drug was
administered for progression. No evidence of radiographic progres-
sion was observed in these patients. The fourth group, “Clinical
mCRPC,” consisted of mCRPC patients with both biochemical failure
(rising serial PSA levels above a previous nadir) and appearance of
Table 1
Clinical characteristics of patients in different states of metastatic prostate cancer progression.
Untreated mHSPC group (n = 99) mHSPC on ADT
group
Biochemical progressive
mCRPC group
Clinical mCPRC
group
Entire group, n = 97 3-month mHSPC
subgroup, n = 29
Total patients, no. 97 37 40 81 85
Patients with analyzable NGS data (N) 73 29 33 75 69
Age in years at the time specimen collection, median
(range)
66 (4590) 70 (4590) 71 (5089) 70 (5287) 72 (5092)
PSA at time of sample collection, median ng/ml (IQR)
First sample 6.35 (1.028.3) 11.20 (4.024.5) 0.53 (0.05.6) 2.8 (0.68.5) 16.7 (4.560.5)
Second sample N/A 0.94 (030.6) N/A N/A N/A
ALP at the time of sample collection, median (range) 80 (39485) 77 (46255) 82 (42670) 78 (34392) 99.5 (44605)
Metastatic Volume, no.
Low 47 20 NA NA NA
High 22 7 NA NA NA
Unknown 4 2 NA NA NA
Median time from ADT initiation for mHSPC stage to
biochemically progress to CRPC stage, mo (range)
14.98 (078.5) 17.9 (7.3357.8) 15.93 (1.2130.43) 15.70 (0211.67) 16.77 (3.2184.8)
Median follow up time from date of HSPC specimen
collection to last follow up, mo (range)
94.53 (0.03107.3) 97.07 (25.37107.3) 85.17 (0104.73) N/A N/A
Median time from ADT initiation to failure, mo
(range)
14.99 (078.5) 16.77 (7.3357.8) 15.93 (1.2130.43)
Median time for mHSPC patients from initiation of
ADT to death/last follow up, mo (range)
71.2 (1.13115.1) 75.8 (25.37106.93) 63 (0.33141.33) N/A N/A
Median follow-up time from date of mCRPC specimen
collection to last follow up, mo (range)
N/A N/A N/A 74.7 (1.53102.77) 94.67 (1.694.67)
Median time to death/last follow-up for mCRPC
patients, mo (range)
N/A N/A N/A 43.33 (0102.77) 25.93 (1.694.67)
Patients progressed on ADT, no. 34 16 23 N/A N/A
Patients dead upon follow-up, no. 38 15 20 58 62
All demographic data mentioned above only relate to NGS-analyzable patients. Disease progression in subjects diagnosed and treated for localized stage disease was
defined by the treating physician on the basis of either serial PSA rise on 2 separate occasions after achieving a posttreatment nadir PSA value or appearance of new
radiological disease or with the initiation of a new cancer-specific intervention, whichever came first. ADT initiation for the hormone-sensitive stage was defined by the
treating physician and included either serial PSA rise on 2 separate occasions after achieving a nadir PSA value or appearance of new radiological disease or with the ini-
tiation of a new cancer specific intervention, whichever came first. Biochemical progression to mCRPC stage during ADT for mHSPC was defined by the treating physician
and included either serial PSA rise on 2 separate occasions after achieving a nadir PSA value during ongoing continuous ADT or the initiation of a secondary hormonal
maneuver whichever came first. Clinical progression to CRPC stage during ADT for the hormone-sensitive stage was defined as the first appearance of new radiological
disease or the initiation of a new cancer-specific intervention, whichever came first during ongoing continuous ADT.
Abbreviations: ADT, androgen deprivation therapy; ALP, alkaline phosphatase; IQR, interquartile range (2575); mCRPC, metastatic castrate-resistant prostate cancer;
mHSPC, metastatic hormone-sensitive prostate cancer; mo, months; N/A, not applicable; NGS, next generation sequencing; PSA, prostate-specific antigen.
4 M. Kohli et al. / EBioMedicine 54 (2020) 102728new radiographic metastases, with the sample collection performed
before any new drug addition for progressive disease. The demo-
graphic data of all patients enrolled in each group are detailed in
Table 1 and Supplementary Table S1.
3.1. cfDNA, ctDNA, pTMB distributions in progressive metastatic
prostate cancer states
We calculated the cfDNA yield and ctDNA fraction and the num-
ber of variants in the coding regions of the genes covered by the
panel (denoted as pTMB) for all patients in the 4 groups and com-
pared the overall group and intergroup-wise distributions for differ-
ences (Table 2). The per group distributions and comparisons
between them are also shown in Supplementary Figure S2 (cfDNA),
Fig. 1A (ctDNA), and Fig. 1B (pTMB). cfDNA yield/ctDNA fraction and
pTMB levels were significantly greater in the mCRPC groups than in
the mHSPC groups (P< ¢001, KruskalWallis test). There were no dif-
ferences in cfDNA yield/ctDNA fraction or in the pTMB levels between
untreated mHSPC and mHSPC on ADT groups.
A median cfDNA yield cutoff value of 9¢6 ng/mL was used for all
study samples based on which the ctDNA fraction distribution was
determined (top panel of Fig. 1C). The ECOG 3805 CHAARTED trial’s
[6] definition of high- and low- volume metastatic disease was used
to stratify high vs low metastatic volume in the untreated metastatic
hormone-sensitive group. Fig. 1C (middle panel) shows the distribu-
tion of ctDNA fractions in high- and low- volume metastatic disease.
The lower panel in Fig. 1C shows ctDNA fraction distributions above
and below the median serum alkaline phosphatase (ALP) levels(median, 83 IU/L), a known prognostic factor for survival in castra-
tion-resistant state [25].
The impact of metastatic volume on cfDNA yield/ctDNA fraction
and pTMB is shown in Supplementary Figures S3 (A-C) and detailed
in the Supplementary Results. Change in nucleic acid yields under
the effect of ADT after 3 months of treatment in 29 paired mHSPC
samples is detailed in Table 2, Supplementary Figures S4, and the
Supplementary Results with an observed decrease in ctDNA fraction.
Supplementary Figure S5 shows no significant changes in cfDNA
yield/ctDNA fraction after prolonged ADT exposure compared to
samples analyzed after 3 months of ADT.
3.2. ctDNA/cfDNA yields and clinical outcomes
To determine the impact of cfDNA yield/ctDNA fraction and pTMB
levels on clinical outcomes, we evaluated the predictive value of
these variables for ADT efficacy in patients in the untreated mHSPC
group using ADT failure time and assessed their prognostic value for
OS in patients in mHSPC and mCRPC states (Supplementary Results).
Supplementary Figure S6 summarizes the prognostic and predictive
(to ADT) value of cfDNA yield/ctDNA fraction/pTMB in mHSPC state.
As anticipated, patients with high-volume metastatic disease in
the untreated mHSPC group had the shortest OS (Supplementary
Figure 7SA); however, metastatic volume was not predictive of the
duration of ADT failure (Supplementary Figure 7SB). We further
explored the combined effect of cfDNA yield/ctDNA fraction and met-
astatic disease volume on survival. Untreated mHSPC patients with
high-volume metastatic disease and high-yield cfDNA/ctDNA had the
Table 2
cfDNA, ctDNA, and mutational load tumor profile across metastatic prostate cancer states.
Untreated mHSPC group
n=73
Serial 3-month mHSPC
group (n =29/73)
mHSPC on ADT group
(n= 33)
Biochemical Progressive
CRPC group (n = 75)
Clinical mCRPC group
(n =69)
Median cfDNA, ng/ml (range) 4.32 (1.58212.88) 4.2 (1.7810.67) 3.7 (1.6103.56) 12.26 (3.8784.71) 17.97 (5.54678.86)
Group comparison of cfDNA yields,
type (P value)
Untreated vs 3-month ADT treated (P = .22)
(N = 29)
3-month post ADT vs
continuous ADT
(P = .83)
Untreated mHSPC vs
biochemical CRPC
relapse (P< .001)
Untreated mHSPC vs
clinical CRPC
(P< .001)
Median ctDNA fraction (range) 0.01(0.0060.63) 0.009 (0.0060.23) 0.01(0.0060.92) 0.01(0.0060.76) 0.04(0.0060.75)
Group comparison of ctDNA fraction,
type (P value)
Untreated vs 3-month ADT treated (P = .02)
(N = 29)
3-month post ADT vs
continuous ADT
(P = .79)
Untreated mHSPC vs
biochemical CRPC
relapse (P< .001)
Untreated mHSPC vs
clinical CRPC
(P< .001)
pTMB variantsa, no. 3 (128) 4 (112) 3 (113) 5 (141) 5 (128)
pTMB-based group comparisons,
type (P value)
Untreated vs 3-month ADT treated (P = .18)
(N = 29)
3-month post ADT vs
continuous ADT
(P = .47)
Untreated mHSPC vs
biochemical CRPC
relapse (P< .001)
Untreated mHSPC vs
clinical CRPC
(P< .001)
pTMB-based group comparisons for
mHSPC state vs. mCRPC, P value
NA NA NA P< .001
a Number of variants in the coding region covered by the panel.
Abbreviations: ADT, androgen deprivation therapy; cfDNA, circulating free DNA; ctDNA, circulating tumor DNA; CRPC, castrate-resistant prostate cancer; mCRPC, metastatic
castrate-resistant prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer; NA, not applicable; pTMB, plasma tumor mutational burden.
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low cfDNA yield/ctDNA fraction had the longest OS. Interestingly, not
all patients with high-volume metastatic disease had poor OS, as a
group of mHSPC patients with high-volume metastatic disease andFig. 1. A. Distribution of ctDNA fractions across metastatic groups with significant differe
kalWallis test). B. Distribution of plasma-based tumor mutation burden across groups. C. Di
tive group and serum alkaline phosphatase (ALP) in mCRPC states. Samples are dichotomized
mL) and ALP levels (Median: 83 IU/L), respectively. Percentage of samples with different ctD
ctDNA fraction and metastatic volume for the prediction of ADT failure in mHSPC patients. H
across the samples. E. Overall survival in the mHSPC group based on the combined analysis
analysis of ctDNA fraction and serum ALP levels of overall survival in mCRPC patients.low nucleic acid yields had intermediate OS similar to those of
patients with low-volume metastatic disease and high cfDNA yield/
ctDNA fraction. Fig. 1D shows the Kaplan-Meier plots for OS based on
volume status and ctDNA fraction in the untreated mHSPC group.nces in yield observed across the 4 independent groups of patients (P < . 001, Krus-
stribution of cfDNA yields based on metastatic volume in the untreated hormone-sensi-
into low and high groups based on the median value of cfDNA yields (median: 9.6 ng/
NA fractions are shown in different colors for each description. D. Combined analysis of
igh and low ctDNA fractions are defined based on the third quartile of ctDNA fraction
of volume of metastatic disease with ctDNA fraction in mHSPC patients. F. Combined
6 M. Kohli et al. / EBioMedicine 54 (2020) 102728Fig. 1E shows the combined effect of ctDNA fraction and metastatic
disease volume on ADT failure rates; patients with high-volume
metastases and high ctDNA fraction exhibited the shortest time to
ADT failure.
The prognostic value of ALP levels on OS, a known clinical prog-
nostic factor in mCRPC, was determined (Supplementary Figure S8)
and nucleic acid yield/fractionbased prognosis evaluated (Supple-
mentary Figure S9). The combined effect of ALP and nucleic acid
yield/fraction on OS for all mCRPC patients is shown in Fig. 1F for
ctDNA and Supplementary Figure S10 for cfDNA, and detailed results
are presented in the Supplementary Results. Results of nucleic acid-
based prognosis on OS in the subset of patients with clinical mCRPC
alone is shown in Supplementary Figures S11A (cfDNA), S11B
(ctDNA), S11C (pTMB), S12A (serum ALP), and S12B and S12C (com-
bined nucleic acid yield/fraction with ALP).
3.3. CNAs, SNVs, and rearrangements in ctDNA
We characterized the spectrum of alterations in each of the 4
independent groups of mHSPC and mCRPC patients. A 120 gene panel
was used to identify ctDNA-based CNAs, SNVs, and the frequency of
TMPRSS2-ERG fusion. Fig. 2 shows the individual patient ctDNA frac-
tions and variant counts (Fig. 2A) of all patients. Fig. 2B shows the
overall distribution of plasma ctDNA somatic alterations in the top 26
genes across the spectrum of all 4 groups (n =250) that were altered
in 3% of the study patients using the targeted 120 gene panel.
Fig. 2C represents deleterious/likely deleterious alterations detected
in genes that were involved in DNA damage repair (DDR) pathways
and includes copy number loss and germline pathogenic mutations.
Supplementary Table S2 describes the number of patients in each
metastatic group who had a genomic alteration of any kind and
shows the intergroup comparisons that were performed. All 3 types
of somatic alterations (SNVs, CNAs, and TMPRSS2-ERG fusions) were
detected more frequently in mCRPC patients than in mHSPC patients.
Within the mCRPC groups, a significantly higher proportion of clinical
mCRPC group patients had somatic events compared to all other
groups (Supplementary Table S2). To identify any effects that cfDNA
yield/ctDNA fraction might have on detecting ctDNA-based events,
we correlated these yields with event frequencies (r2 = 0¢42 for cfDNA
yield; r = 0¢82 for ctDNA fraction) (Supplementary Figure S13). Addi-
tional descriptive details of alteration characteristics are provided in
Supplementary Figure S14 and in the Supplementary Results.
Fig. 2B and C also shows TP53, AR, DDR pathway genes, cell cycle
control and differentiation pathway genes, and well-known tumor
suppressor genes to be among the most frequent genes within the
top 20 genes with detectable somatic alterations. An increased num-
ber of genes in mCRPC patients (n = 33 [23%]) had detectable CNAs
(amplifications/deletions) compared to mHSPC patients (n =8 [8%]).
AR gene amplification was the most common CNA and was largely
detected in the mCRPC group patients. EGFR, MYC, BRAF, and CDK6
gene amplifications were detected in both mHSPC and mCRPC
patients. RB1 deletion/loss was the most frequently detected dele-
tion/loss, and 41/250 patients also had copy number loss of DNA
repair pathway genes (Fig. 2C) in both the mHSPC (n = 14/106) and
mCRPC groups (n = 27/144). An increased number of mCRPC patients
(n =33 [23%]) had detectable CNAs (amplifications/deletions) com-
pared to mHSPC patients (n =8 [8%]).
The overall frequency of ctDNA mutations, which were signifi-
cantly increased in patients in the mCRPC groups compared to
patients in the mHSPC groups (Fig. 3A), were observed in AR, APC,
and KIT genes (P< ¢05). AR hotspot mutations were detectable only in
patients in the mCRPC groups. Fig. 3B shows that these mutations
were in the ligand-binding domain of the receptor and indicates the
number of patients with each mutation. Previously reported muta-
tions T742L, T742C, V716M, T878A, L702H, H875Y and other novel
hotspot AR mutations were among those detected in patients in themCRPC groups [26], but we did not detect the previously reported
F788L mutation in this cohort. Fig. 3C further shows the distribution
of AR hotspot mutations across exon regions in mCRPC patients at
the different levels of variant allelic frequency of detection. Fig. 3D
shows the per-patient occurrence of detectable AR mutations, AR
copy number gain, and individual patient-level ctDNA fractions in
both mCRPC groups.
Co-occurrence of multiple somatic mutations in individual genes
across the spectrum of metastatic groups was also observed in select
patients, with a higher number detected in the mCRPC groups than in
the mHSPC groups. In the clinical mCRPC and biochemical progres-
sive mCRPC patients (11 [16%] and 3 [4%], respectively), cooccurrence
of multiple somatic mutations was detected in TP53, APC, BRCA2,
RBI1, CDK12, and ARID1A. In the untreated mHSPC patients (2 [3%]),
multi-hits were detected in 2 genes: BRCA2 and NF1.
Of the 250 patients profiled for ctDNA alterations, we were able to
successfully sequence the gDNA of 219 to probe for germline patho-
genic variations in key genes. Pathogenic variants were detected in
20/219 patients, including 11/92 patients in the mHSPC and 9/127 in
mCRPC groups. Nine patients had both germline and somatic ctDNA
alterations in DDR genes. Fig. 2C shows patients with cooccurrence of
pathogenic germline variants and somatic alterations in key genes
throughout the spectrum of progression.
3.4. ctDNA clonal dynamic changes after ADT initiation in paired plasma
of untreated mHSPC patients
Pharmacodynamic changes in ctDNA-based alterations were
interrogated before and after 3 months of ADT in the 29 paired
plasma collections of the untreated mHSPC group patients (n =29;
[40%]). Changes in PSA (Fig. 4A), ctDNA fractions (Fig. 4B) and specific
clonal changes of the most frequently mutated genes before and after
3 months of ADT treatment in the untreated mHSPC group are shown
in Fig. 4C. After 3 months of ADT, several patients demonstrated a
PSA response but not a complete disappearance of plasma ctDNA
fraction and/or detectable mutations (Fig. 4B). Appearance of new
mutations after 3 months of ADT with PSA response was also
observed (Fig. 4C: patients 1175, 1284, 1054, and 1073).
3.5. Comparison of ctDNA-based alterations in 2 independent clinical
mCRPC cohorts
We compared our findings from the Mayo Clinic clinical mCRPC
group (n =69) to an independent second matched cohort of 34 clini-
cal mCRPC patients from Monash Health and Chris O’Brien Lifehouse,
Australia, who underwent plasma ctDNA profiling. The baseline
demographic profile of the Australian clinical mCRPC cohort is pro-
vided in Supplementary Table S3. We observed similar frequencies of
ctDNA-based perturbations between the Mayo Clinic and Australian
cohorts in key altered genes: TP53, AR, BRCA2, and BRAF (Supplemen-
tary Figure S15). These data highlight common findings of genomic
alterations in 2 independent racially matched cohorts (for example,
near similar AR amplification frequency [23% vs. 20%]).
3.6. Plasma ctDNA alterations and clinical outcomes
The effect of plasma ctDNA-based alterations on clinical outcomes
among the mHSPC and mCRPC groups was determined in the Mayo
Clinic longitudinal cohort. Median time from date of specimen collec-
tion to death/last follow-up for each independent group in provided
in Table 1. Several patients in each group were not detected to have
alteration events (Supplementary Table S2). Among untreated
mHSPC patients (n = 21 [29%]) without detectable alterations, the
median OS was 86¢5 months (95% CI, 49¢27; not reached). Among
untreated mHSPC patients (n =53 [73%]) with detectable alterations,
the median OS was 66¢4 (range, 53¢6; not reached) months (HR, 1¢27
Fig. 2. A: Individual patient ctDNA fractions and variant counts across metastatic groups. B. Overall heatmap of individual somatic alterations observed in metastatic prostate cancer
groups. C. Overall heatmap of deleterious/likely deleterious alterations detected in genes involved in DNA damage repair pathways. Copy number loss is shown as a blue box, and
germline deleterious/likely deleterious mutations are marked with a green diamond shape.
M. Kohli et al. / EBioMedicine 54 (2020) 102728 7[95% CI, 0¢622¢64]; P = ¢51) (Supplementary Figure S16A). Pres-
ence of detectable somatic events did not affect ADT failure rates
(Supplementary Figure S16B). In comparison, in the mCRPC groups,
patients not detected to have somatic events had a significantly lon-
ger OS than mCRPC patients with detected events (54¢6 vs 30¢93
months; HR, 1¢84 [95% CI, 0¢993¢43]; Log-Rank P = .05) (Supple-
mentary Figure S16C). We also explored MSI status and correlation
with plasma TMB in mHSPC/mCRPC patients detected with MMR-
deficiency mutations (and/or MSI-high status, hypermutation) and
are reported under “Supplementary Results” and Supplementary
Figure S17.OS outcomes were also determined for the mHSPC and mCRPC
groups on the basis of individual-gene and multiple-gene alterations
after adjusting for known prognostic variables in both groups. In
untreated mHSPC patients at the individual-gene level, alterations in
TP53 and ATMwere significantly associatedwith shorter OS. These alter-
ations were not significant after adjusting for metastatic volume and
Gleason Score. Collectively, untreated mHSPC patients with somatic
alterations detected in multiple DNA repair genes (ATM, BRCA1, BRCA2,
and CHEK2) had significantly short OS (HR, 4¢0 [95% CI, 1¢411¢8];
P = 4¢75 £ 1005) (Supplementary Table S4) and a shorter time to fail-
ure with ADT even after adjusting for clinical prognostic factors.
Fig. 3. A. Alteration frequencies in key genes between mCRPC and mHSPC groups. B. Lollipop plot of AR somatic mutations detected in mHSPC and mCRPC patients. Known hotspot
AR mutations are labeled with detailed amino acid changes. C. Distribution of AR hotspot mutations across exon regions in mCRPC patients. Each dot represents a patient, and the
distinct colors indicate different levels of variant allelic frequency (VAF). D. Distribution of AR mutations and AR copy number gain along with matching ctDNA fractions in mCRPC
patients detected with these alterations. Each colored bar represents an individual patient.
Fig. 4. A. PSA changes after 3-months of ADT in untreated mHSPC paired patient samples. B. ctDNA fraction changes after 3-months of ADT in untreatedmHSPC paired patient samples.
C. ctDNA-based somatic alterations of top frequently mutated genes detected in 29 paired untreated mHSPC patients before and after 3 months of androgen deprivation therapy.
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prognostic value for poor outcomes in multivariate analyses after
adjusting for Gleason Score and ALP levels (HR, 4.2 [95% CI, 2.08.7];
P =1.5 £ 04). Somatic perturbations detected in other genes in mul-
tivariable analyses that had prognostic significance included TP53,
CDH1, CDK6 and BRCA2 (Supplementary Table S5). At the individual
gene level, Fig. 5A shows RB1 copy number deletion to be associated
with significantly worse OS in mCRPC patients. Similarly, Fig. 5B
shows poor OS in mCRPC patients with AR copy number gain. mCRPC
patients who harbored different TP53 mutations and an increasing
number of mutations were also associated with poorer OS (Fig. 5C).
4. Discussion
A comprehensive analysis of the genomic landscape of metastatic
prostate cancer, frommHSPC to clinical and radiographically progres-
sive mCRPC, and its impact on clinical outcomes has not been eluci-
dated. In metastatic prostate cancer, somatic mutational variations
have been extensively profiled in the castrate-resistant state
[11,12,2730], and prognostic and predictive genomic perturbations
identified. However, in practice, it is difficult to obtain tissue biopsies
of progressive metastatic prostate cancer before ADT initiation, dur-
ing response to ADT, and at the time of ADT initiation. At the same
time, this uncharacterized and uncaptured underlying clonal evolu-
tion in the continuum of progressive metastatic states is likely to
result in cumulative late-stage alterations. This longitudinal cohort
study aimed to fill the gap in this continuum, from the untreated
mHSPC state to the development of castration resistance, by profiling
plasma ctDNA-based alterations in the coding regions of 120 key
biology-specific cancer and prostate cancer genes. Because radio-
graphic and clinical symptoms of mHSPC patients who progress on
ADT typically follow biochemical failure (defined as rising serum PSA
levels and often used in clinical practice for additional therapeutic
interventions) by a median of 8 months, we separately delineated
somatic genomic alterations in mCRPC patients experiencing bio-
chemical and radiographic/clinical progressions [6]. Although our
study was not designed to be a predictive and prognostic biomarker
study, follow-up data obtained from this longitudinal cohort allowed
for us to comprehensively profile the clinical relevance of the struc-
tural DNA-based variations observed in each of these metastatic
groups with clinical outcomes.
We report several interesting findings in our study, which add
practical value beyond currently used clinical factors. We observed
that ctDNA fraction may serve as prognostic factors in mHSPC and
mCRPC patients. mHSPC patients with low ctDNA fraction and low-
volume metastatic disease status achieved better OS than patients
with high-volume disease and/or high ctDNA fraction. These data ifFig. 5. A. RB1 wild type vs copy number deletion and overall survival in mCRPC patients. B.
TP53mutations vs wild type and overall survival in mCRPC patients.validated prospectively may serve in selecting patients for the inten-
sification of upfront systemic treatment beyond known clinical fac-
tors to achieve optimal OS in patients with high-volume disease and/
or high ctDNA yield. Until now, the selection of patients for treat-
ments additional to ADT has been guided using non-genomic clinical
factors such as Gleason Score, the presence of visceral metastases,
and/or the number of skeletal metastases. With an increasing array
of systemic treatment options available to mHSPC patients [5,31],
these data potentially provide further insights into selection of initial
therapy for metastatic prostate cancer based on the circulatory and
measurable tumor genome and the presence or absence of key geno-
mic perturbations.
Similarly, among mCRPC patients, we observed a poor prognosis
subgroup of patients with high ctDNA fraction and high levels of
serum ALP, which a known clinical poor prognostic marker. These
results suggest that these patients could be the focus of clinical trials
testing more aggressive combination therapies. Notably, in both
mHSPC and mCRPC patients, pTMB levels were not strongly linked to
clinical outcomes, suggesting that pTMB is not a useful biomarker in
advanced prostate cancer. This finding is consistent with the low
mutational burden observed in prostate cancer [32], particularly in
comparison to malignancies such as lung cancer and melanoma [33].
We identified several genes in which alterations were associated
with clinical outcomes in both mHSPC and mCRPC patients which
have potential therapeutic impact. In mHSPC patients, perturbations
in the TP53 and DDR genes (ATM + BRCA 1/2 § CHEK2) were signifi-
cantly associated with survival after adjusting for several clinical fac-
tors, although not for ADT treatment failure. In mCRPC state,
alterations in TP53, RB1, BRCA2, CDK6, and CHD1 were linked to
shorter rates of OS. It would appear that inactivation of tumor sup-
pressor genes and selected DDR genes appears to confer worse out-
comes in advanced prostate cancer. It is increasingly recognized that
the loss of function of key tumor suppressor genes, including TP53,
RB1, and PTEN,may be a poor prognostic marker for both mHSPC and
mCRPC patients [30,34,35], and our ctDNA-based results largely sup-
port this finding. Although the prognostic value of DDR gene altera-
tions for mCRPC patients is controversial [36,37], their prognostic
significance for mHSPC patients is largely unknown; our findings sug-
gest that patients with composite DDR alterations have poor rates of
OS. This will require independent and prospective validation.
The emergence of somatic alterations in the mCRPC state in 2
independent cohorts (the biochemical progressive mCRPC group and
the clinical mCRPC group), has not been consistently reported.
Mayrhofer et al. [38] recently conducted a small study in which
plasma-based genomes of hormone-naive and castrate-resistant
patients were compared using ctDNA genome profiling. The authors
reported ctDNA and ctDNA-based somatic variations in 6 hormone-AR copy number gain compared to wild type and overall survival in mCRPC patients. C.
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which were used to evaluate variations in cfDNA/ctDNA and genomic
alterations from the hormone-naive to the castrate-resistant state.
Given this study’s limited number of patients and the distinctive sub-
set of patients with biochemical and radiographic breakdown at the
time of castration resistance, it is difficult to draw conclusions regard-
ing clinical effects or to create an atlas of changes across the spectrum
of progression. In our study of larger mCRPC cohorts, we observed
qualitative and quantitative differences in genomic perturbations
between these 2 mCRPC groups, with a greater accumulation of
mutational alterations detected with radiographic progression than
biochemical progression alone while on ADT. It is unclear whether
these differences in genomic perturbations will have clinical implica-
tions. However, the emergence of cumulative and novel somatic per-
turbations at the time of ADT failure, which can be detected earlier in
their course has value for impacting practice, as these alterations
could be used to monitor minimally progressive disease as well as
provide a potential therapeutic advantage for earlier interventions
that affect clinical outcomes.
Another key application of ctDNA profiling in metastatic prostate
cancer is the facilitation of personalized medicine therapeutics. Given
the recently announced PROfound clinical trial results [39], in which
olaparib was found to significantly improve radiographic progres-
sion-free survival in patients with BRCA 1/2 or ATM aberrant mCRPC,
it is notable that we detected BRCA 1/2 or ATM perturbations in 16%
of our mCRPC cohort. Use of a ctDNA assay could spare these patients
the need to undergo a potentially painful tumor biopsy procedure or
to be treated with androgen receptor pathway inhibitors, as the trial
results indicate a better radiographic progression-free survival rate
with olaparib. Likewise, we observed PTEN or PIK3CA changes in 25
patients, who may be suitable candidates for inhibitors targeting the
PI3K/AKT pathway, such as ipatasertib, which is currently being stud-
ied in phase III clinical trials in patients with mCRPC [40].
Additionally, ctDNA is advantageous because serial blood samples
are readily obtainable, allowing for the identification of patients with
early treatment failure due to the rapid emergence of adaptive resis-
tance, such as specific AR mutations in biochemically progressive
mCRPC state. Notably, in the mHSPC state, early genomic changes
also arose in TP53 and ATM even when patients experienced bio-
chemical responses with declining serum PSA levels. These early
genomic changes emphasize the genomic plasticity of prostate cancer
under testosterone suppression. These changes may also play a key
biological role in tumor suppressor and DDR genes in advanced pros-
tate cancer and may be used to monitor minimal residual disease.
However, realizing the clinical value of ctDNA-based profiling for this
indication will require greater future effort.
4.1. Limitations
We were unable to evaluate the effect of treatments using serial
sampling in most of our patients to determine therapy selection pres-
sure on clonal evolutionary perturbations. This will require a system-
atic study in future. We also did not evaluate intronic structural
variations, which can be twice as common in genes such as RB1 and
PTEN. Our attempt was to go beyond cataloging aberrations in single
genes and pathways, and thus, we used a custom panel of 120 can-
cer-related genes. At the same time, this cancer panel did not include
all possible cancer genomic aberrations, such as ERG gene rearrange-
ments. There is at least a risk of underestimation of tumor fraction
due to missing tumor DNA that does not harbor alterations in any of
the genes included on the custom panel. A more comprehensive
genome-wide determination will need to be conducted to more accu-
rately capture somatic variants and tumor fractions. Additionally, in
our study, we observed when the ctDNA fraction was low, as noted
for 15% of our study cohort, that ctDNA profiling may not have been
sensitive enough to detect key alterations. Nevertheless, the use ofctDNA profiling to follow the emergence of cumulative genomic
alterations in the blood is a potentially powerful tool for monitoring
minimal residual disease, therapeutic targeting, and accurate prog-
nostication of survival in metastatic-stage prostate cancer; however,
further validation is needed.
5. Conclusions
In our study, ctDNA fraction before, during, and after ADT failure
may appear to refine known clinical prognostic factors across the
spectrum of metastatic prostate cancer, and this will need future vali-
dation. We also detected specific ctDNA alterations in mCRPC that
correlate with poorer survival, as do mutations in multiple DNA
repair genes observed to be predictive of ADT efficacy and survival in
the hormone-sensitive state. The molecular characterization of pro-
gressive metastatic prostate cancer also supports the rational match-
ing of a growing armamentarium of drug choices for metastatic
prostate cancer states. Finally, molecular profiling, with or without
nucleic acid yields, may be useful for monitoring minimal residual
disease in metastatic prostate cancer, for which further validation is
needed.
Declaration of Competing Interest
Manish Kohli received travel/accommodation from Celgene; Tian-
tian Zheng, Amy Wang, Carlos Montesinos, Calven Wong, Pan Du,
Shidong Jia, and Jianjun Yu are stockholders in Predicine, Inc.; Lisa
Horvath received research funding from Astellas Pharma, travel/
accommodation from Astellas Pharma and Pfizer, and is on the Scien-
tific Advisory Board for Imagion; Kate Mahon received travel/accom-
modation from Astellas Pharma; Edmond M Kwan received
honoraria from Janssen, research funding from Astellas Pharma and
AstraZeneca, and travel /accommodations from Astellas Pharma,
Pfizer, and Ipsen; Arun A Azad is a consultant for Astellas Pharma,
Janssen, and Novartis, is on the speakers bureau for Astellas Pharma,
Janssen, Novartis and Amgen received honoraria from Astellas
Pharma, Janssen, Novartis, Tolmar, Amgen, Pfizer, and Telix, is on the
Scientific Advisory Board for Astellas Pharma, Novartis, Sanofi, Astra-
Zeneca, Tolmar, Pfizer, and Telix, and received research funding from
Astellas Pharma, and Merck Serono.
Acknowledgments
We thank Paul Fletcher and Daley Drucker (Moffitt Cancer Center)
for editorial assistance. They were not compensated beyond their
regular salaries.
Funding
This study was based on a non-commercial collaboration between
academic institutions. No funding was received from Predicine, Inc.
during the conduct of the study.
This study was supported by: NHMRC Postgraduate Scholarship
(to Edmond M Kwan); Movember/Prostate Cancer Foundation of Aus-
tralia Clinical Scientist Fellow (CSA 0515; to Kate Mahon); the Astel-
las Investigator-Initiated Grant, Cancer Institute NSW Translational
Program Grant (2018/TPG001; to Lisa G Horvath); the NHMRC Project
Grant, Victorian Cancer Agency Clinical Research Fellowship-
CRF14009, Astellas Investigator-Initiated Grant, NHMRC Project
Grant - GNT1098647 (to Arun A Azad); and the National Institute of
Health- RO1-CA212097 (to Manish Kohli).
Supplementary materials
Supplementary material associated with this article can be found
in the online version at doi:10.1016/j.ebiom.2020.102728.
M. Kohli et al. / EBioMedicine 54 (2020) 102728 11References
[1] Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, et al. Blood-based
tumor mutational burden as a predictor of clinical benefit in non-small-cell lung
cancer patients treated with atezolizumab. Nat Med 2018;24(9):1441–8.
[2] Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, et al. Blood-based
tumor mutational burden as a predictor of clinical benefit in non-small-cell lung
cancer patients treated with atezolizumab. Nat. Med. 2018;24(9):1441.
[3] Basch E, Loblaw DA, Rumble RB. Systemic therapy in men with metastatic castra-
tion-resistant prostate cancer: American Society of Clinical Oncology and Cancer
Care Ontario Clinical Practice guideline summary. J Oncol Pract 2014;10(6):
e418–e20.
[4] Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-
Repair defects and Olaparib in metastatic prostate cancer. N Engl J Med 2015;373
(18):1697–708.
[5] Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzaluta-
mide with standard first-line therapy in metastatic prostate cancer. New Engl J
Med 2019;381(2):121–31.
[6] Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemo-
hormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med
2015;373(8):737–46.
[7] Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al.
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk
metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival
analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 2019;20
(5):686–700.
[8] James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al.
Abiraterone for prostate cancer not previously treated with hormone therapy. N
Engl J Med 2017;377(4):377338–51.
[9] Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apaluta-
mide treatment and metastasis-free survival in prostate cancer. N Engl J Med
2018;378(15):1408–18.
[10] James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al.
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone
therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multi-
arm, multistage, platform randomised controlled trial. Lancet 2016;387
(10024):1163–77.
[11] Wang L, Dehm SM, Hillman DW, Sicotte H, TanW, Gormley M, et al. A prospective
genome-wide study of prostate cancer metastases reveals association of WNT
pathway activation and increased cell cycle proliferation with primary resistance
to abiraterone acetate-prednisone. Ann Oncol 2017;29(2):352–60.
[12] Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Inte-
grative clinical genomics of advanced prostate cancer. Cell 2015;161(5):1215–28.
[13] Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The
mutational landscape of lethal castration-resistant prostate cancer. Nature
2012;487(7406):239–43.
[14] Jimenez RE, Atwell TD, Sicotte H, Eckloff B, Wang L, Barman P, et al. A prospective
correlation of tissue histopathology with nucleic acid yield in metastatic castra-
tion-resistant prostate cancer biopsy specimens. Mayo Clin Proc Innov Qual Out-
comes 2019;3(1):14–22.
[15] Xia S, Kohli M, Du M, Dittmar RL, Lee A, Nandy D, et al. Plasma genetic and geno-
mic abnormalities predict treatment response and clinical outcome in advanced
prostate cancer. Oncotarget 2015;6(18):16411–21.
[16] Binder M, Zhang BY, Hillman DW, Kohli R, Kohli T, Lee A, et al. Common genetic
variation in CYP17A1 and response to abiraterone acetate in patients with meta-
static castration-resistant prostate cancer. Int J Mol Sci 2016;17(7):1097.
[17] Zhang BY, Riska SM, Mahoney DW, Costello BA, Kohli R, Quevedo JF, et al. Germ-
line genetic variation in JAK2 as a prognostic marker in castration-resistant pros-
tate cancer. BJU Int 2016.
[18] Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, et al. Exosomal miR-1290 and
miR-375 as prognostic markers in castration-resistant prostate cancer. Eur. Urol.
2015;67(1):33–41.
[19] Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler
transform. Bioinformatics 2009;25(14):1754–60.
[20] Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, et al. Inte-
grated digital error suppression for improved detection of circulating tumor DNA.
Nat Biotechnol 2016;34(5):547–55.[21] Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensi-
tive detection of somatic point mutations in impure and heterogeneous cancer
samples. Nat. Biotechnol. 2013;31(3):213–9.
[22] Vandekerkhove G, Todenhofer T, Annala M, Struss WJ, Wong A, Beja K, et al. Cir-
culating tumor DNA reveals clinically actionable somatic genome of metastatic
bladder cancer. Clin Cancer Res 2017;23(21):6487–97.
[23] Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and
powerful approach to multiple testing. J R Stat Soc: Ser B (Methodol) 1995;57
(1):289–300.
[24] Quintanal-Villalonga A, Molina-Pinelo S, Cirauqui C, Ojeda-Marquez L, Marrugal
A, Suarez R, et al. FGFR1 cooperates with EGFR in lung cancer oncogenesis, and
their combined inhibition shows improved efficacy. J Thorac Oncol 2019;14
(4):641–55.
[25] Halabi S, Lin CY, Small EJ, Armstrong AJ, Kaplan EB, Petrylak D, et al. Prognostic
model predicting metastatic castration-resistant prostate cancer survival in men
treated with second-line chemotherapy. J Natl Cancer Inst 2013;105(22):1729–
37.
[26] Sumiyoshi T, Mizuno K, Yamasaki T, Miyazaki Y, Makino Y, Okasho K, et al. Clinical
utility of androgen receptor gene aberrations in circulating cell-free DNA as a bio-
marker for treatment of castration-resistant prostate cancer. Sci Rep 2019;9
(1):4030.
[27] Beltran H, Eng K, Mosquera JM, Sigaras A, Romanel A, Rennert H, et al. Whole-
exome sequencing of metastatic cancer and biomarkers of treatment response.
JAMA Oncol 2015;1(4):466–74.
[28] Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, et al. Genomic
hallmarks and structural variation in metastatic prostate cancer. Cell 2018;174
(3):758–69 e9.
[29] Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, et al. The long tail of
oncogenic drivers in prostate cancer. Nat Genet 2018;50(5):645–51.
[30] Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic corre-
lates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A
2019;116(23):11428–36.
[31] Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R,
et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J
Med 2019;381(1):13–24.
[32] Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, et al. Prospective
comprehensive genomic profiling of primary and metastatic prostate tumors. JCO
Precis Oncol 2019(3):1–23.
[33] Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al.
Signatures of mutational processes in human cancer. Nature 2013;500
(7463):415–21.
[34] Hamid AA, Gray KP, Shaw G, MacConaill LE, Evan C, Bernard B, et al. Compound
genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and
metastatic prostate cancer. Eur Urol 2019;76(1):89–97.
[35] De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, et al.
TP53 outperforms other androgen receptor biomarkers to predict abiraterone or
enzalutamide outcome in metastatic castration-resistant prostate cancer. Clin
Cancer Res 2019;25(6):1766–73.
[36] Nombela P, Lozano R, Aytes A, Mateo J, Olmos D, Castro E. BRCA2 and other DDR
genes in prostate cancer. Cancers (Basel) 2019;11(3):352.
[37] Schweizer MT, Antonarakis ES. Prognostic and therapeutic implications of DNA
repair gene mutations in advanced prostate cancer. Clin Adv Hematol Oncol
2017;15(10):785–95.
[38] Mayrhofer M, De Laere B, Whitington T, Van Oyen P, Ghysel C, Ampe J, et al. Cell-
free DNA profiling of metastatic prostate cancer reveals microsatellite instability,
structural rearrangements and clonal hematopoiesis. Genome Med 2018;10
(1):85.
[39] Hussain M, Mateo J, Fizazi K, Saad F, Shore ND, Sandhu S, et al. LBA12_PRPRO-
found: phase III study of olaparib versus enzalutamide or abiraterone for meta-
static castration-resistant prostate cancer (mCRPC) with homologous
recombination repair (HRR) gene alterations. Ann Oncol 2019;30(Suppl 5)
mdz394.039.
[40] Bono JSD, Giorgi UD, Massard C, Bracarda S, Kocak I, Font A, et al. Randomized
phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi)
vs. Abi alone in patients with metastatic castration-resistant prostate cancer
(mCRPC) after docetaxel chemotherapy (A. Martin study). J Clin Oncol. 2016;34
(15_suppl):5017.
